ITM2C | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
plasmacytoid dendritic cell	29 studies	85% ± 13%	Explore
fibroblast	27 studies	37% ± 20%	Explore
plasma cell	26 studies	63% ± 23%	Explore
pericyte	22 studies	50% ± 23%	Explore
B cell	19 studies	28% ± 12%	Explore
smooth muscle cell	18 studies	44% ± 25%	Explore
CD8-positive, alpha-beta T cell	18 studies	32% ± 10%	Explore
mast cell	17 studies	44% ± 16%	Explore
astrocyte	15 studies	39% ± 13%	Explore
connective tissue cell	14 studies	50% ± 25%	Explore
endothelial cell	14 studies	31% ± 13%	Explore
epithelial cell	13 studies	50% ± 23%	Explore
memory B cell	12 studies	21% ± 3%	Explore
plasmablast	11 studies	72% ± 19%	Explore
T cell	11 studies	36% ± 24%	Explore
oligodendrocyte precursor cell	10 studies	46% ± 20%	Explore
myofibroblast cell	10 studies	53% ± 27%	Explore
IgG plasma cell	10 studies	55% ± 17%	Explore
gamma-delta T cell	10 studies	31% ± 10%	Explore
progenitor cell	9 studies	50% ± 23%	Explore
goblet cell	9 studies	55% ± 23%	Explore
IgA plasma cell	9 studies	52% ± 21%	Explore
macrophage	8 studies	40% ± 15%	Explore
natural killer cell	8 studies	29% ± 14%	Explore
CD8-positive, alpha-beta memory T cell	7 studies	30% ± 7%	Explore
enterocyte	7 studies	46% ± 23%	Explore
glutamatergic neuron	7 studies	28% ± 15%	Explore
GABAergic neuron	6 studies	31% ± 14%	Explore
conventional dendritic cell	6 studies	34% ± 20%	Explore
kidney loop of Henle epithelial cell	6 studies	39% ± 20%	Explore
neuron	6 studies	40% ± 15%	Explore
hematopoietic stem cell	6 studies	40% ± 16%	Explore
precursor B cell	6 studies	49% ± 15%	Explore
dendritic cell	6 studies	35% ± 10%	Explore
immature B cell	6 studies	55% ± 18%	Explore
mature NK T cell	6 studies	32% ± 14%	Explore
innate lymphoid cell	6 studies	27% ± 6%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	5 studies	22% ± 2%	Explore
CD4-positive, alpha-beta T cell	5 studies	24% ± 7%	Explore
abnormal cell	5 studies	32% ± 22%	Explore
mesothelial cell	5 studies	49% ± 16%	Explore
transit amplifying cell	5 studies	53% ± 21%	Explore
retinal cone cell	5 studies	64% ± 24%	Explore
pro-B cell	5 studies	42% ± 8%	Explore
brush cell	5 studies	51% ± 16%	Explore
regulatory T cell	5 studies	32% ± 14%	Explore
hematopoietic precursor cell	4 studies	69% ± 16%	Explore
exhausted T cell	4 studies	35% ± 8%	Explore
pancreatic A cell	4 studies	54% ± 14%	Explore
type B pancreatic cell	4 studies	41% ± 17%	Explore
effector memory CD8-positive, alpha-beta T cell	4 studies	25% ± 3%	Explore
kidney distal convoluted tubule epithelial cell	4 studies	80% ± 19%	Explore
enteroendocrine cell	4 studies	48% ± 18%	Explore
intestinal crypt stem cell	4 studies	54% ± 13%	Explore
leukocyte	4 studies	30% ± 2%	Explore
amacrine cell	4 studies	37% ± 18%	Explore
CD16-negative, CD56-bright natural killer cell, human	4 studies	36% ± 19%	Explore
T-helper 17 cell	4 studies	32% ± 17%	Explore
basal cell	4 studies	29% ± 9%	Explore
group 3 innate lymphoid cell	4 studies	59% ± 19%	Explore
retina horizontal cell	4 studies	33% ± 14%	Explore
ciliated cell	4 studies	30% ± 13%	Explore
naive B cell	4 studies	27% ± 15%	Explore
pancreatic D cell	3 studies	68% ± 16%	Explore
endothelial cell of lymphatic vessel	3 studies	48% ± 17%	Explore
retinal bipolar neuron	3 studies	67% ± 16%	Explore
OFF-bipolar cell	3 studies	33% ± 14%	Explore
ON-bipolar cell	3 studies	44% ± 19%	Explore
GABAergic amacrine cell	3 studies	26% ± 9%	Explore
common myeloid progenitor	3 studies	43% ± 25%	Explore
retinal pigment epithelial cell	3 studies	53% ± 24%	Explore
intraepithelial lymphocyte	3 studies	41% ± 21%	Explore
Mueller cell	3 studies	37% ± 10%	Explore
rod bipolar cell	3 studies	76% ± 17%	Explore
effector memory CD4-positive, alpha-beta T cell	3 studies	20% ± 4%	Explore
effector CD8-positive, alpha-beta T cell	3 studies	25% ± 8%	Explore
pancreatic ductal cell	3 studies	51% ± 12%	Explore
glial cell	3 studies	54% ± 26%	Explore
mucosal invariant T cell	3 studies	20% ± 1%	Explore
interneuron	3 studies	26% ± 9%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
intestine	14 studies	42% ± 23%	Explore
brain	13 studies	26% ± 12%	Explore
kidney	7 studies	31% ± 16%	Explore
eye	7 studies	33% ± 13%	Explore
pancreas	4 studies	44% ± 18%	Explore
placenta	4 studies	29% ± 15%	Explore
lung	4 studies	46% ± 15%	Explore
bone marrow	4 studies	25% ± 7%	Explore
lymph node	3 studies	19% ± 3%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
brain	97%	47637.29	2550 / 2642	100%	1561.89	703 / 705
intestine	99%	38339.52	960 / 966	86%	523.45	453 / 527
prostate	93%	8891.71	228 / 245	87%	233.77	437 / 502
kidney	97%	15699.43	86 / 89	68%	168.24	614 / 901
bladder	76%	8990.95	16 / 21	78%	340.88	391 / 504
ovary	76%	6109.73	136 / 180	68%	270.71	293 / 430
uterus	83%	8222.18	141 / 170	58%	339.93	268 / 459
stomach	67%	5308.74	242 / 359	71%	310.66	204 / 286
thymus	50%	3050.35	328 / 653	84%	341.92	506 / 605
pancreas	16%	911.42	54 / 328	94%	267.87	168 / 178
lung	36%	2080.57	207 / 578	75%	164.57	866 / 1155
skin	24%	1859.47	436 / 1809	85%	326.81	402 / 472
eye	0%	0	0 / 0	99%	399.85	79 / 80
esophagus	60%	5561.19	867 / 1445	38%	71.44	69 / 183
spleen	97%	10204.44	233 / 241	0%	0	0 / 0
adrenal gland	18%	1479.03	47 / 258	76%	723.14	175 / 230
tonsil	0%	0	0 / 0	58%	106.64	26 / 45
blood vessel	47%	4876.23	625 / 1335	0%	0	0 / 0
breast	16%	1026.90	75 / 459	24%	46.82	269 / 1118
liver	3%	172.25	7 / 226	22%	38.36	89 / 406
peripheral blood	20%	2580.82	184 / 929	0%	0	0 / 0
heart	19%	1061.82	165 / 861	0%	0	0 / 0
adipose	17%	1080.39	209 / 1204	0%	0	0 / 0
lymph node	0%	0	0 / 0	10%	26.00	3 / 29
muscle	0%	5.36	1 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0030182	Biological process	neuron differentiation
GO_2001238	Biological process	positive regulation of extrinsic apoptotic signaling pathway
GO_0010977	Biological process	negative regulation of neuron projection development
GO_0042985	Biological process	negative regulation of amyloid precursor protein biosynthetic process
GO_0005764	Cellular component	lysosome
GO_0070062	Cellular component	extracellular exosome
GO_0005794	Cellular component	Golgi apparatus
GO_0005886	Cellular component	plasma membrane
GO_0005765	Cellular component	lysosomal membrane
GO_0048471	Cellular component	perinuclear region of cytoplasm
GO_0001540	Molecular function	amyloid-beta binding
GO_0005515	Molecular function	protein binding
GO_0005524	Molecular function	ATP binding

IV. Literature review

[source]

Gene name	ITM2C
Protein name	Cerebral protein-3 (Integral membrane protein 2C) Integral membrane protein 2C (Cerebral protein 14) (Transmembrane protein BRI3) [Cleaved into: CT-BRI3] Integral membrane protein 2
Synonyms	hucep-14 hCG_34338 hucep-3 PSEC0047 NPD018 BRI3
Description	FUNCTION: Negative regulator of amyloid-beta peptide production. May inhibit the processing of APP by blocking its access to alpha- and beta-secretase. Binding to the beta-secretase-cleaved APP C-terminal fragment is negligible, suggesting that ITM2C is a poor gamma-secretase cleavage inhibitor. May play a role in TNF-induced cell death and neuronal differentiation (By similarity). . FUNCTION: Negative regulator of amyloid-beta peptide production. May inhibit the processing of APP by blocking its access to alpha- and beta-secretase. Binding to the beta-secretase-cleaved APP C-terminal fragment is negligible, suggesting that ITM2C is a poor gamma-secretase cleavage inhibitor. May play a role in TNF-induced cell death and neuronal differentiation. . FUNCTION: Negative regulator of amyloid-beta peptide production. May inhibit the processing of APP by blocking its access to alpha- and beta-secretase. Binding to the beta-secretase-cleaved APP C-terminal fragment is negligible, suggesting that ITM2C is a poor gamma-secretase cleavage inhibitor. May play a role in TNF-induced cell death and neuronal differentiation. . FUNCTION: Negative regulator of amyloid-beta peptide production. May inhibit the processing of APP by blocking its access to alpha- and beta-secretase. Binding to the beta-secretase-cleaved APP C-terminal fragment is negligible, suggesting that ITM2C is a poor gamma-secretase cleavage inhibitor. May play a role in TNF-induced cell death and neuronal differentiation. . FUNCTION: Negative regulator of amyloid-beta peptide production. May inhibit the processing of APP by blocking its access to alpha- and beta-secretase. Binding to the beta-secretase-cleaved APP C-terminal fragment is negligible, suggesting that ITM2C is a poor gamma-secretase cleavage inhibitor. May play a role in TNF-induced cell death and neuronal differentiation. .
Accessions	E7EUS6 ENST00000326407.10 [Q9NQX7-3] B8ZZM6 Q96JS4 Q9NQX7 ENST00000620962.1 ENST00000326427.11 [Q9NQX7-1] ENST00000543957.5 ENST00000409704.6 C9JG41 ENST00000418408.2 ENST00000541852.5 ENST00000335005.10 [Q9NQX7-2] ENST00000457215.5 F5H4I5

ITM2C report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review